证券代码：603108 证券简称：润达医疗 公告编号：临2025-063 转债代码：113588 转债简称：润达转债 上海润达医疗科技股份有限公司 关于增加2025年度日常关联交易预计的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 因公司业务发展的需要，依据实际情况，增加与关联方2025年度日常关联交易预计的金额。 ● 本次日常关联交易不会导致公司对关联方形成依赖，不会影响上市公司的独立性。 ● 本次增加的日常关联交易金额在公司董事会审批范围之内，无需提交股东会审议。 一、增加日常关联交易履行的审议程序 2024年12月4日，公司第五届董事会第十九次会议审议通过了《关于公司2025年度日常关联交易预计的 议案》，关联董事回避表决。该议案经过公司2024年第三次临时股东大会审议通过，关联股东回避表 决。2025年内，公司经过第五届董事会第二十三次会议及第五届董事会第二十四次会议审议，分别通过 了《关于增加2025年度日常关联交易预计的议案》，关联董事回避表决。 2025年12月26日，公司第五届董事会 ...

Core Viewpoint - The company plans to increase the estimated amount of daily related party transactions for 2025 due to business development needs, ensuring that this will not affect its independence or reliance on related parties [1][2]. Group 1: Increase in Related Party Transactions - The company intends to increase the estimated amount of daily related party transactions for 2025 from 500 million RMB to 6.9 billion RMB, primarily due to new product demands from a related party, Guorun Medical Supply Chain Service (Shanghai) Co., Ltd [1]. - The increase in related party transactions has been approved by the board of directors and does not require shareholder meeting approval [1]. Group 2: Related Party Information - Guorun Medical Supply Chain Service (Shanghai) Co., Ltd is a subsidiary of a company in which the company holds shares, and it specializes in providing comprehensive services for medical laboratories [1]. - As of December 31, 2024, Guorun Supply Chain had total assets of 2.44 billion RMB and net assets of 734.38 million RMB, with an annual revenue of 1.00 billion RMB [1]. Group 3: Transaction Purpose and Impact - The related party transactions are necessary for the company's normal business operations and are conducted on fair and voluntary terms, ensuring no harm to the interests of the company or its shareholders [2]. - The pricing policy for these transactions is based on market fair prices, and they do not significantly impact the company's assets or profit situation [2].